Author(s)

Lassina Traore^1,2, Nouhoun Nignan¹, Sanata Kiemde¹, Abdoul Rasmané Koumbem¹, Sidnooma Véronique Zongo^1,2, Minane Nafissa Triande¹, Abdoul Karim Ouattara^1,2,3, Marie Simone Traore¹, Tegwindé Rébéca Compaore^1,2,4, Tani Sagna^1,3, Ina Marie Traore¹, Albert Théophane Yonli^1,2, Bolni Marius Nagalo⁵, Florencia Wendkuuni Djigma^1,2*, Jacques Simpore^1,2

¹Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE),Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso.
²Biomolecular Research Center Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
³Université Norbert Zongo, Centre Universitaire Manga, Koudougou, Burkina Faso.
⁴Biomedical Research Laboratory (LaReBio), Biomedical and Public Health Department, Institute for Research in Health Sciences (IRSS/CNRST), Ouaga, Burkina Faso.
⁵Division of Hematology and Oncology, Mayo Clinic, Scottsdale, USA.

Introduction: Hepatic diseases comprise inflammations of the liver, which can originate from drug-induced, toxic, autoimmune sources and particularly hepatitis B and C virus infection. The outcome of the disease is linked to interactions between the immune system and the virus, and also depends on the age and immune status of the patient. The aim of this study was to evaluate the association of a MAP3K14 (rs2074292), CD40 (rs1883832) polymorphism and chronic hepatitis B virus carriage in a population from Burkina Faso. Methods: In this case-control analysis, 223 and 173 samples, consisting of 90 and 53 controls and 133 and 120 cases, were examined for MAP3K14 and CD40 respectively. The cases included patients with Chronic Hepatitis B (CHB), cirrhosis or hepatocellular carcinoma (HCC). Genomic DNA extraction was executed using INVITROGEN and FAVORGEN kits. Genotyping of MAP3K14 (rs2074292) and CD40 (rs1883832) gene polymorphisms was accomplished via real-time PCR on the QuantStudioTM 5 Real-Time instrument, followed by allelic discrimination using TaqMan Genotyper Software. Data was interpreted using SPSS version 20 and Epi info version 7.5.2.0. Odds ratios (OR), confidence intervals (CI), and p-values were derived for risk and significance evaluation. Results: This study showed that the heterozygous CT genotype and the mutated T allele of the CD40 (rs1883832) gene are involved in the progression of chronic hepatitis to cirrhosis and hepatocellular carcinoma in HBV-infected patients. However, no association was found between polymorphisms in the MAP3K14 gene (rs2074292) and the progression of HBV infection. By combining the two polymorphisms, we observed either high risk or protection, depending on the genotypes of the MAP3K14 and CD40 genes simultaneously carried by the patient. Conclusion: Polymorphisms of the MAP3K14 and CD40 genes are associated with the evolution of HBV infection.

Polymorphisms, MAP3K14, CD40, HBV and Burkina Faso

Traore, L. , Nignan, N. , Kiemde, S. , Koumbem, A. , Zongo, S. , Triande, M. , Ouattara, A. , Traore, M. , Compaore, T. , Sagna, T. , Traore, I. , Yonli, A. , Nagalo, B. , Djigma, F. and Simpore, J. (2023) Involvement of CD40 (rs1883832) and MAP3K14 (rs2074292) Genes Polymorphisms in Hepatitis B Virus Infection in Burkina Faso, West Africa. Journal of Biosciences and Medicines, 11, 343-361. doi: 10.4236/jbm.2023.1112026.